468 related articles for article (PubMed ID: 27037973)
21. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
23. Onabotulinum toxin injection in neurogenic detrusor overactivity: intradetrusor versus suburothelial.
Burki JR; Hamid R
Spinal Cord; 2013 Sep; 51(9):725. PubMed ID: 23774129
[No Abstract] [Full Text] [Related]
24. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
Ghalayini IF; Al-Ghazo MA
Neurourol Urodyn; 2007; 26(4):531-536. PubMed ID: 17330289
[TBL] [Abstract][Full Text] [Related]
25. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
26. How to define failure of intradetrusor injections of botulinum toxin A for neurogenic detrusor overactivity.
Mailho C; Peyronnet B; De Seze M; Even A; Perrouin-Verbe MA; Amarenco G; Chartier-Kastler E; Le Normand L; Manunta A; Karsenty G; Kerdraon J; Ruffion A; Saussine C; Le Breton F; Bernuz B; Castel-Lacanal E; Denys P; Phé V; Gamé X
Neurourol Urodyn; 2024 Apr; 43(4):811-817. PubMed ID: 38451038
[TBL] [Abstract][Full Text] [Related]
27. Response to ‘Onabotulinum toxin injection in neurogenic detrusor overactivity: intradetrusor versus suburothelial’.
Krhut J; Samal V; Nemec D; Zvara P
Spinal Cord; 2013 Sep; 51(9):726. PubMed ID: 23797569
[No Abstract] [Full Text] [Related]
28. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity.
Joussain C; Popoff M; Phé V; Even A; Bosset PO; Pottier S; Falcou L; Levy J; Vaugier I; Chartier Kastler E; Schurch B; Denys P
Neurourol Urodyn; 2018 Feb; 37(2):799-806. PubMed ID: 28745807
[TBL] [Abstract][Full Text] [Related]
30. Switching from onabotulinum toxin A to abobotulinum toxin A for treating detrusor overactivity in spinal cord injured patient, does it really work?
Le Roy C; Lefèvre C; Lepoittevin L; Reiss B; Le Fort M; Rigaud J; Perrouin-Verbe B; Perrouin-Verbe MA
Prog Urol; 2023 Sep; 33(10):503-508. PubMed ID: 37550178
[TBL] [Abstract][Full Text] [Related]
31. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
Grosse J; Kramer G; Stöhrer M
Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
[TBL] [Abstract][Full Text] [Related]
32. Botulinum injection is useless on fibrotic neuropathic bladders.
Tiryaki S; Yagmur I; Parlar Y; Ozel K; Akyildiz C; Avanoglu A; Ulman I
J Pediatr Urol; 2015 Feb; 11(1):27.e1-4. PubMed ID: 25448589
[TBL] [Abstract][Full Text] [Related]
33. [Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey].
Peyronnet B; Sanson S; Amarenco G; Castel-Lacanal E; Chartier-Kastler E; Charvier K; Damphousse M; Denys P; de Seze M; Egon G; Even A; Forin V; Karsenty G; Kerdraon J; le Normand L; Loche CM; Manunta A; Mouracade P; Phe V; Previnaire JG; Ruffion A; Saussine C; Schurch B; Game X;
Prog Urol; 2015 Dec; 25(17):1219-24. PubMed ID: 26318394
[TBL] [Abstract][Full Text] [Related]
34. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
Krhut J; Samal V; Nemec D; Zvara P
Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
[TBL] [Abstract][Full Text] [Related]
35. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
36. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
[TBL] [Abstract][Full Text] [Related]
37. [bobotulinum toxin A (Dysport) for the treatment of neurogenic detrusor overactivity].
Krivoborodov GG; Kuzmin IV; Romikh VV
Urologiia; 2023 May; (2):122-129. PubMed ID: 37401717
[TBL] [Abstract][Full Text] [Related]
38. Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity.
Behr-Roussel D; Oger S; Pignol B; Pham E; Le Maux A; Chabrier PE; Caisey S; Compagnie S; Picaut P; Bernabé J; Alexandre L; Giuliano F; Denys P
Eur Urol; 2012 May; 61(5):1054-61. PubMed ID: 22341129
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients.
Deffontaines-Rufin S; Weil M; Verollet D; Peyrat L; Amarenco G
Int Braz J Urol; 2011; 37(5):642-8. PubMed ID: 22099277
[TBL] [Abstract][Full Text] [Related]
40. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.
Kalsi V; Apostolidis A; Popat R; Gonzales G; Fowler CJ; Dasgupta P
Eur Urol; 2006 Mar; 49(3):528-35. PubMed ID: 16426735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
